NY money manager charged in $1 8 billion Ponzi-like fraud - Netscape Money & Business netscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from netscape.com Daily Mail and Mail on Sunday newspapers.
Updated on January 22, 2021 at 5:57 pm
NBCUniversal, Inc.
Infusions of monoclonal antibodies are one of the few treatments with promise to keep people with COVID-19 from getting so sick, they wind up in the emergency room.
Researchers from Baylor University Medical Center recently published findings from their latest study, proving that monoclonal antibodies reduce hospitalizations among patients at high risk of complications from COVID-19.
Dr. Robert Gottlieb of Baylor University Medical Center and a lead author of the study says those given a combination of antibodies in the first few days of their illness had lower levels of virus days later and were less likely to visit the hospital than those given a placebo.
Judge commits Great Neck woman to psychiatric institution after fatal stabbing newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
Associated Press
Emily Schubert, the employee health nurse at the Alaska Native Medical Center in Anchorage, Alaska, prepares a COVID-19 vaccine shot on Tuesday, Dec. 15, 2020. Front-line health care workers are among the first in Alaska to receive the vaccine.
It will be months before the general public can get vaccinated against COVID-19. But those who’ve recovered from it are believed to have antibodies offering protection from the virus.
KERA’s Sam Baker talked about how long antibody and vaccine protection lasts with Dr. Robert Gottlieb of Baylor, Scott and White Hospital System. He led clinical trials in North Texas on the COVID treatment, Remdesivir, and is researching a COVID-19 vaccine for Johnson and Johnson.